DONGKOO BIO & PHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,620 KRW | -0.75% |
|
-1.93% | +16.96% |
| Sales 2022 | 195B 143M 197M | Sales 2023 | 216B 158M 218M | Capitalization | 156B 115M 158M |
|---|---|---|---|---|---|
| Net income 2022 | 6.61B 4.85M 6.68M | Net income 2023 | 11.81B 8.67M 11.93M | EV / Sales 2022 | 0.87 x |
| Net cash position 2022 | 814M 597K 822K | Net Debt 2023 | 20.91B 15.35M 21.12M | EV / Sales 2023 | 0.82 x |
| P/E ratio 2022 |
25.8
x | P/E ratio 2023 |
13.2
x | Employees | 355 |
| Yield 2022 |
1.79% | Yield 2023 |
2.12% | Free-Float | 54.59% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.75% | ||
| 1 week | -1.93% | ||
| Current month | -0.90% | ||
| 1 month | +8.70% | ||
| 3 months | +11.82% | ||
| 6 months | +28.29% | ||
| Current year | +16.96% |
1 week
6 510.00
6 890.00
1 month
5 860.007 110.00
Current year
5 320.007 110.00
1 year
4 615.007 110.00
3 years
4 615.0010 900.00
5 years
3 533.3315 833.33
10 years
3 533.3315 833.33
| Managers | Title | Age | Since |
|---|---|---|---|
Yong-Joon Cho
CEO | Chief Executive Officer | 58 | - |
Yoon-Sik Kim
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Yong-Woo Kim
BRD | Director/Board Member | 50 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Hong Park
BRD | Director/Board Member | 61 | - |
Yong-Joon Cho
CEO | Chief Executive Officer | 58 | - |
In-Su Mun
BRD | Director/Board Member | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 6,620 | -0.75% | 141,840 |
| 24-05-02 | 6,670 | -0.15% | 242,100 |
| 24-04-30 | 6,680 | -2.48% | 264,858 |
| 24-04-29 | 6,850 | +1.48% | 156,051 |
| 24-04-26 | 6,750 | -2.32% | 235,384 |
End-of-day quote Korea S.E., May 02, 2024
More quotes
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +16.96% | 135M | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- A006620 Stock
